Praxis Precision Ownership
| PRAX Stock | USD 37.71 0.59 1.59% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 18.9 M | Current Value 20 M | Avarage Shares Outstanding 6 M | Quarterly Volatility 6.2 M |
Praxis |
Praxis Stock Ownership Analysis
About 100.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.68. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Praxis Precision Med has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 10.21. The firm had not issued any dividends in recent years. Praxis Precision had 1:15 split on the 29th of November 2023. Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company was incorporated in 2015 and is based in Boston, Massachusetts. Praxis Precision operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. To find out more about Praxis Precision Medicines contact Marcio MBA at 617 300 8460 or learn more at https://praxismedicines.com.Besides selling stocks to institutional investors, Praxis Precision also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Praxis Precision's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Praxis Precision's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Praxis Precision Quarterly Liabilities And Stockholders Equity |
|
Praxis Precision Insider Trades History
Less than 1% of Praxis Precision Medicines are currently held by insiders. Unlike Praxis Precision's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Praxis Precision's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Praxis Precision's insider trades
Praxis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Praxis Precision is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Praxis Precision Medicines backward and forwards among themselves. Praxis Precision's institutional investor refers to the entity that pools money to purchase Praxis Precision's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-12-31 | 605 K | Assenagon Asset Management Sa | 2024-12-31 | 559.1 K | Point72 Asset Management, L.p. | 2024-12-31 | 521.3 K | Verition Fund Managegment, Llc | 2024-12-31 | 464.5 K | Geode Capital Management, Llc | 2024-12-31 | 406.7 K | Franklin Resources Inc | 2024-12-31 | 389.8 K | Cibc Global Asset Management Inc | 2024-12-31 | 366.8 K | Baker Bros Advisors Lp | 2024-12-31 | 331.5 K | Nuveen Asset Management, Llc | 2024-12-31 | 306.9 K | Cormorant Asset Management, Llc | 2024-12-31 | 1.7 M | Blackrock Inc | 2024-12-31 | 1.5 M |
Praxis Precision Med Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Praxis Precision insiders, such as employees or executives, is commonly permitted as long as it does not rely on Praxis Precision's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Praxis Precision insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Praxis Precision Outstanding Bonds
Praxis Precision issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Praxis Precision Med uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Praxis bonds can be classified according to their maturity, which is the date when Praxis Precision Medicines has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| PRAXAIR INC 355 Corp BondUS74005PBD50 | View | |
| US74005PBT03 Corp BondUS74005PBT03 | View | |
| PRAXAIR INC 32 Corp BondUS74005PBQ63 | View | |
| US74005PBS20 Corp BondUS74005PBS20 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Praxis Precision Corporate Filings
| 19th of March 2025 Other Reports | ViewVerify | |
8K | 28th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 14th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Praxis Stock Analysis
When running Praxis Precision's price analysis, check to measure Praxis Precision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Praxis Precision is operating at the current time. Most of Praxis Precision's value examination focuses on studying past and present price action to predict the probability of Praxis Precision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Praxis Precision's price. Additionally, you may evaluate how the addition of Praxis Precision to your portfolios can decrease your overall portfolio volatility.